Targeting gene expression to hypoxic tumor cells

Nature Medicine

Volumn 3, Issue 5, 1997, Pages 515-520

  Dachs, Gabi U ^a,b   Patterson, Adam V ^a,c,d   Firth, John D ^c,e   Ratcliffe, Peter J ^c   Stuart Townsend, K M ^a   Stratford, Ian J ^a,d   Harris, Adrian L ^c  

^a MEDICAL RESEARCH COUNCIL   (United Kingdom)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCYTOSINE; FLUOROURACIL;

ARTICLE; CANCER CELL; CANCER THERAPY; CELL CULTURE; CELL HYPOXIA; FIBROSARCOMA; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

EID: 0030968939     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0597-515     Document Type: Article

References (27)

1. Kasahara, N., Dozy, A. & Kan, Y. Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science 266, 1373-1376 (1994).
2. Manome, Y., Abe, M., Hagen, M., Fine, H. & Kufe, D. Enhancer sequences of the DF3 gene regulate expression of the herpes simplex virus thymidine kinase gene. Cancer Res. 54, 5408-5413 (1994).
3. Hallahan, D.E. et al. Spatial and temporal control of gene therapy using ionizing radiation. Nature Med. 1, 786-791 (1995).
4. Folkman, J. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 82, 4-6 (1989).
5. Vaupel, P.W. Oxygenation of solid tumors. in Drug Resistance in Oncology. (Teicher, B.A., ed.) 53-85 (Marcel Dekker, New York, 1993).
6. Hoeckel, M., Schlenger, K., Mitze, M., Schaeffer, U. & Vaupel, P. Hypoxia and radiation response in human tumors. Semin. Radiat. Oncol. 6, l-8 (1996).
7. Bunn, H.F. & Poyton, R.O. Oxygen sensing and molecular adaptation to hypoxia. Physiol. Rev. 76, 839-885 (1996).
8. Dachs, G.U. & Stratford, I.J. The molecular response of mammalian cells to hypoxia and the potential for exploitation in cancer therapy, Br. J. Cancer 74, S126-132 (1996).
9. Wang, G.L. & Semenza, G.L. General involvement of hypoxia-inducible factor-1 in transcriptional response to hypoxia. Proc. Natl. Acad. Sci. USA 90, 4304-4308 (1993).
10. 2 tension. Proc. Natl. Acad. Sci. USA 92, 5510-5514 (1995).
11. Firth, J.D., Ebert, B.L., Pugh, C.W. & Ratcliffe, P.J. Oxygen regulated elements in the phosphoglycerate kinase-1 and lactate dehydrogenase A genes: Similarities with the erythropoietin 3′ enhancer. Proc. Natl. Acad. Sci. USA 91, 6496-6500 (1994).
12. Poon, M.A. et al. Biochemical modulation of 5-fluorouracil Ñ evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J. Clin. Oncol. 7, 1407-1418 (1989).
13. Mullen, C.A., Kilstrup, M. & Blaese, R.M. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc. Natl. Acad. Sci. USA 89, 33-37 (1992).
14. Olive, P.L. Detection of hypoxia by measurement of DNA damage in individual cells from spheroid and murine tumors exposed to bioreductive drugs. II. RSU1069. Br. J. Cancer 71, 537-542 (1995).
15. Adams, G.E., Ahmed, I., Sheldon, P.W. & Stratford, I.J. Radiation sensitization and chemopotentiation: RSU-1069, a compound more efficient than misonidazole in vitro and in vivo. Br. J. Cancer 49, 571-577 (1984).
16. Connors, T.A. The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. Gene Ther. 2, 702-709 (1995).
17. Maxwell, P.H., Pugh, C.W. & Ratcliffe, P.J. Inducible expression of the erythropoietin 3′ enhancer in multiple cell lines: Evidence for a widespread oxygen-sensing mechanism. Proc. Natl. Acad. Sci. USA 90, 2423-2427 (1993).
18. Pugh, C.W., Ebert, B.L., Ebrahim, O. & Ratcliffe, P.J. Characterization of functional domains within the mouse erythropoietin 3′ enhancer conveying oxygen regulated responses different cell-lines. Biochim. Biophys. Acta 1217, 297-306 (1994).
19. Levy, A.P., Levy, N.S., Wegner, S. & Goldberg, M.A. Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J. Biol. Chem. 270, 13333-13340 (1995).
20. Shweiki, D., Itin, A., Soffer, D. & Keshet, E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359, 843-845 (1992).
21. Stein, I., Neeman, M., Shweiki, D., Itin, A. & Keshet, E. Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and co-regulation with other ischemia-induced genes. Mol. Cell. Biol. 15, 5363-5368 (1995).
22. Workman, P. & Stratford, I.J. The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metastasis Rev. 12, 73-82 (1993).
23. Moulder, J.E., Dutreix, J., Rockwell, S. & Siemann, D.W. Applicability of animal tumor data to cancer-therapy in humans. Int. J. Rad. Oncol. Biol. Phys. 14, 913-927 (1988).
24. Chaplin, D.J. & Hill, S.A. Temporal heterogeneity in microregional erythrocyte flux in experimental solid tumors. Br. J. Cancer 71, 1210-1213 (1995).
25. Watling, D. et al. Complementation by the protein tyrosine kinase JAK2 of a mutant cell line defective in the interferon-γ (signal transduction pathway. Nature 366, 166-170 (1993)
26. Andersen, L., Kilstrup, M. & Neuhard, J. Pyrimidine, purine and nitrogen control of CD synthesis in Escherichia coli K12: Involvement of the glnLG and the purR genes in the regulation of codA expression. Arch. Microbiol. 152, 115-118 (1989).
27. Stratford, I.J. & Stephens, M.A. The differential hypoxic cytotoxicity of bioreductive agents determined in vitro by the MTT assay. Int. J. Radiat. Oncol. Biol. Phys. 16, 973-976 (1989).